Assessing non-significant coronary artery disease lesions using advanced imaging techniques

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective cohort study involves 250 patients with suspected or known chronic coronary syndrome who have at least one intermediate coronary lesion. Participants undergo coronary computed tomography angiography (CCTA) and fractional flow reserve (FFR) testing to evaluate the significance of their lesions. Data on patient demographics and lesion characteristics are collected, and patients are monitored for major adverse cardiovascular events (MACE) over one year. The study aims to improve the understanding of non-significant coronary artery disease lesions and their management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients were enrolled if they had at least one intermediate coronary lesion (classified as 50-70% diameter stenosis on visual judgment) on CCTA and then underwent FFR testing

Exclusion Criteria:

* Patients having past coronary artery bypass graft surgery (CABG)
* previous PCI in the target vascular
* significant renal impairment define with eGFR \< 30 mL/min/1.73 m²
* contrast allergy
* poor image quality that prevented appropriate CCTA or CT-FFR analysis

Where it's running

• Professor Kojuri Cardiology Clinic
  Shiraz, Fars, Iran Recruiting

Study contacts

• Study coordinator: javad UOM kojuri
• Email: kojurij@yahoo.com
• Phone: 09171115083

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Common femoral vein-to-artery diameter ratio to detect elevated LVEDP

  Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.

  Recruiting Burapha University · Chon Buri · NCT07866859

• Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI

  This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.

  Recruiting Jilin University · Changchun, Jilin · NCT07846462

• See if stopping long-term aspirin is as good as continuing it in older adults with stable ischemic heart disease

  In adults 65 and older with stable ischemic heart disease, this trial tests whether stopping daily low-dose aspirin is not worse than continuing it.

  Recruiting at 2 sites Phase 4 Odense University Hospital · Copenhagen and 1 other locations · NCT07795398

• IVUS-Guided Left Main Stenting: IVUS-Guided vs Trained-Eye Approach

  This trial tests whether using IVUS to guide left main bifurcation stenting is as good as using an angiography-driven, experience-based approach by an IVUS-savvy operator.

  Recruiting Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health · Saint Petersburg · NCT07711106

• Can CZT-SPECT/CT quantify myocardial tracer uptake to match PET measurements in coronary artery disease?

  This study tests whether CZT-SPECT/CT can quantify heart blood flow at rest and stress and see if the results align with PET measurements for people with coronary artery disease.

  Recruiting Centre Hospitalier Régional d'Orléans · Orléans, Loiret · NCT07708805

• Ultrasound vs CT calcium scoring to reclassify symptomatic chest pain

  This study tests whether carotid ultrasound can reclassify risk in adults with chest pain and suspected chronic coronary syndrome, compared with the CT calcium score.

  Recruiting London North West Healthcare NHS Trust · Harrow · NCT07696533

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.